BACKGROUNDDiscovery Collaboration Agreement • November 14th, 2001 • Array Biopharma Inc • Services-medical laboratories • Washington
RECITALSDiscovery Collaboration Agreement • May 1st, 2001 • Arqule Inc • Pharmaceutical preparations • Massachusetts
FOURTH AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDiscovery Collaboration Agreement • November 4th, 2008 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 4 (“Fourth Amendment”), effective as of July 25, 2008 (“Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
ARTICLE 1DRUG DISCOVERY COLLABORATION AGREEMENTDiscovery Collaboration Agreement • August 12th, 2013 • Array Biopharma Inc • Pharmaceutical preparations • New York
This DRUG DISCOVERY COLLABORATION AGREEMENT (the “Agreement”), effective as of July 3, 2013 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), and Loxo Oncology, Inc., a Delaware corporation, having an address at c/o Aisling Capital, 888 7th Avenue, 30th Floor, New York, New York 10106 (“Loxo”).
DISCOVERY COLLABORATION AGREEMENT between PHARMACOPEIA, INC. and BRISTOL-MYERS SQUIBB COMPANYDiscovery Collaboration Agreement • March 6th, 2008 • Pharmacopeia Inc • Services-commercial physical & biological research • Delaware
THIS DISCOVERY COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of October 11, 2007 (the “Effective Date”), by and between Bristol-Myers Squibb Company, a Delaware Corporation (“BMS”) and Pharmacopeia, Inc., a Delaware Corporation (“Pharmacopeia”). BMS and Pharmacopeia each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
AMENDMENT OF DISCOVERY COLLABORATION AGREEMENTDiscovery Collaboration Agreement • February 7th, 2020 • Chanticleer Holdings, Inc. • Retail-eating places • California
This Amendment of the Discovery Collaboration Agreement (this “Amendment”) is made and entered into, effective as of May 7, 2019 (the “Effective Date”), by and between XOMA (US) LLC, a Delaware limited liability company having offices at 2200 Powell Street, Suite 310, Emeryville, California, 94608 (“XOMA”) and Sonnet BioTherapeutics, Inc., a New Jersey corporation, having offices ·at 1 Duncan Drive, Cranbury, NJ 08512 (“Sonnet”). Each of XOMA and Sonnet are sometimes referred to herein individually as a “Party” and together as the “Parties.”
SECOND AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDiscovery Collaboration Agreement • February 6th, 2006 • Array Biopharma Inc • Services-medical laboratories
THIS AMENDMENT NO. 2 (“Second Amendment”), effective as of October 1, 2005 (Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”) (collectively, the “Parties” or individually, a “Party”).
FIFTH AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDiscovery Collaboration Agreement • November 4th, 2008 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 5 (“Fifth Amendment”), effective as of September 1, 2008 (“Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
